CARDIOVASCULAR JOURNAL OF AFRICA • Volume 34, No 2, May/June 2023 108 AFRICA intervention to decrease a possible interaction with sLOX-1 expression. Moreover, every sample was tested by ELISA kits in triplicate to prevent technical and biochemical errors. Several potential limitations of this study should be addressed. The sample size of the participants was small, and this was a single-centre study with only one ethnicity selected. Further investigation is necessary in a larger multi-ethnic group and to explore sLOX-1 levels related to other cardiovascular diseases and the patho-physiological pathways. Conclusion Elevated plasma levels of sLOX-1 might be used as a promising potential novel biomarker for early diagnosis of CAD patients. There was a significant association of sLOX-1 with gender and aging. I am grateful to the cardiovascular director of First Xiangya Hospital, Prof Dr Tian lun Yang, and Drs Xia Ke and Li Fei for their continuous help in carrying out this research. My sincere thanks go to the Internal Medicine Department of Jouf University. This work was funded by the deanship of Scientific Research at Jouf University under grant no. DSR-2021-01-03158. References 1. Virani SS, Alvaro AC, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics – 2020 update: A report from the American Heart Association. Circulation 2020; 141: e139–e596. 2. Adam J, Ardissino M, Psaltis PJ. Current approach to the diagnosis of atherosclerotic coronary artery disease: more questions than answers. Ther Adv Chronic Dis 2019; 10: 2040622319884819. 3. Kattoor AJ , Kanuri SH, Mehta JL. Role of Ox-LDL and LOX-1 in atherogenesis. Curr Med Chem 2019; 26: 1693–1700. 4. Stankova T, Delcheva G , Maneva A, Vladeva S. Serum levels of carbamylated LDL and soluble lectin-like oxidized low-density lipoprotein receptor-1 are associated with coronary artery disease in patients with metabolic syndrome. Medicina (Kaunas) 2019; 55(8). 5. Perez L, Vallejos A, Echeverria C, Varela D, Cabello VC, Simon F. OxHDL controls LOX-1 expression and plasma membrane localization through a mechanism dependent on NOX/ROS/NF-κB pathway on endothelial cells. Lab Invest 2019; 99: 421–437. 6. Paquette M, Dufour R, Baass A. Scavenger receptor LOX1 genotype predicts coronary artery disease in patients with familial hypercholesterolemia. Can J Cardiol 2017; 33: 1312–1318. 7. Lubrano V, Pingitore A , Traghella I, Storti S , Parri S , Berti S, et al. Emerging biomarkers of oxidative stress in acute and stable coronary artery disease: levels and determinants. Antioxidants (Basel) 2019; 8(5). 8. Lubrano V, Balzan S. Roles of LOX-1 in microvascular dysfunction. Microvasc Res 2016; 105: 132–140. 9. Junfeng L, Yunde L, Kegang J, Zhixiao H, Qianyu H, Zhili L, et al. Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention. Medicine (Baltimore) 2018; 97: e0366. 10. Zhao ZW, Xu YW, Li SM, Guo JJ, Sun JM, Hong JC, et al. Baseline serum sLOX-1 concentrations are associated with 2-year major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention. Dis Markers 2019: 4925767. 11. Li XM, Jin PP, Xue J, Chen J, Chen QF, Luan XQ , et al. Role of sLOX1 in intracranial artery stenosis and in predicting long-term prognosis of acute ischemic stroke. Brain Behav 2017; 8: e00879. 12. Lee AS, Wang YC, Chang SS, Lo PH, Chang CM, Lu J, et al. Detection of a high ratio of soluble to membrane-bound LOX-1 in aspirated coronary thrombi from patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc 2020; 9: e014008. 13. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics – 2017 update: A report from the American Heart Association. Circulation 2017; 135: e146–e603. 14. Ali Sheikh MS. Over-expression of miR-375 protects cardiomyocyte injury following hypoxic-reoxygenation injury. Oxidative Med Cell Longev 2020; 2020: 7164069. 15. Ali Sheikh MS, Almaeen A, Alduraywish A, Alomair BM, Salma U, Fei L, et al. Overexpression of miR-126 protects hypoxic-reoxygenation exposed HUVEC cellular injury through regulating LRP6 expression. Oxidative Med Cell Longev 2022; 2022: 3647744. 16. Naga VKP, Sotirios KK, Zufeng D , Arockiasamy A , Kottayil IV, Jawahar LM. LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation. J Am Coll Cardiol 2017; 69: 2759–2768. 17. Ali Sheikh MS, Zhenyu Z, Lanyan G, Fei L , Xu D, Hai D , et al. Serum lectin-like oxidized-low density lipoprotein receptor-1 and adiponectin levels are associated with coronary artery disease accompanied with metabolic syndrome. Iran Red Crescent Med J 2014; 16: e12106. 18. Synetos A, Karanasos A, Spyropoulos S , Gazouli M, Latsios G, Toutouzas K, et al. Expression of lectin-like oxidized low-density lipoprotein receptor-1 in human epicardial and intramyocardial coronary arteries of male patients undergoing coronary artery bypass grafting. Cardiology 2018; 139: 203–207. 19. Hofmann A, Brunssen C, Wolk S, Reeps C, Morawietz H. Soluble LOX-1: a novel biomarker in patients with coronary artery disease, stroke, and acute aortic dissection? J Am Heart Assoc 2020; 9: e013803. 20. Jin P, Cong S. LOX-1 and atherosclerotic-related diseases. Clin Chim Acta 2019; 491: 24–29. 21. Misaka T, Suzuki S, Sakamoto N, Yamaki T, Sugimoto K, Kunii H, et al. Significance of soluble lectin-like oxidized LDL receptor-1 levels in systemic and coronary circulation in acute coronary syndrome. Biomed Res Int 2014: 649185. 22. Skarpengland T, Skjelland M, Kong XY, Skagen K, Holm S, Otterdal K, et al. Increased levels of lectin-like oxidized low-density lipoprotein receptor-1 in ischemic stroke and transient ischemic attack. J Am Heart Assoc 2018; 7(2): e006479. 23. Markstad H, Edsfeldt A, Mattison IY, Bengtssoin E, Singh P, Cavalera M, et al. High levels of soluble lectinlike oxidized low-density lipoprotein receptor-1 are associated with carotid plaque inflammation and increased risk of ischemic stroke. J Am Heart Assoc 2019; 8: e009874. 24. Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome –comparison with other biomarkers. J Cardiol 2010; 56: 159–165.
RkJQdWJsaXNoZXIy NDIzNzc=